Tekcapital subsidiary Belluscura fight to battle coronavirus spread

Tekcapital subsidiary Belluscura fight to battle coronavirus spread

Tekcapital (LON:TEK) have said that one of its subsidiaries in Belluscura PLC have filed a patent for an oxygen device which treats respiratory diseases.

Interestingly, Tekcapital noted that the new device could treat patients that had been diagnosed with the coronavirus.

The firm said: “The latest patent application covers devices and systems for treating people suffering from ARDS including patients suffering from the coronavirus.  The primary cause of death from respiratory viruses like the coronavirus and influenza, are the result of the fluids accumulating inside the alveoli (the tiny air sacs of the lungs) which ultimately leads to the failure of the transfer of oxygen to and carbon dioxide out of the blood.  The current primary treatment for ARDS is oxygen therapy along with ventilator support.”

The epidemic of the coronavirus continues to dominate news headlines, and since the outbreak millions have been wiped off Chinese shares and stocks, and the death toll and those infected just continue to rise and rise.

The development from Tekcapital may have come at a time where it may not just benefit the firm, but have global applications.

Despite the numerous attempts from global governments to tackle the coronavirus, it seems that the issue is falling quickly out of hands.

Commenting on the patenting activities, Bob Rauker, CEO of Belluscura, said:

“We are very excited about our next generation oxygen technologies.  With the launch this year of our first product, the X-PLOR™ portable oxygen concentrator, into the respiratory treatment field where over 250 million people suffer from chronic obstructive pulmonary disease (COPD), the third leading cause of death, it is critical that we continue to innovate into the ever-expanding oxygen therapy market.”

Clifford M. Gross Ph.D., Executive Chairman of Tekcapital plc commented:

“We are pleased to see the additional progress of Belluscura as it continues to strengthen its intellectual property in the oxygen therapy space to help patients afflicted with acute respiratory distress caused by the Coronavirus. Additionally, we anticipate that Belluscura is likely to receive FDA clearance for their portable oxygen concentrator within the next 90 days. ”

Tekcapital succeed with Salarius

Tekcapital updated the market in October, which enlightened shareholders about their their portfolio company Salarius Ltd (NASDAQ:SLRX) expanding.

Tekcapital owns 97.5% of the share capital of Salarius ltd. In Salarius portfolio update, consumers were given an insight into Microsalt stating “Salarius, is the developer and manufacturer of a proprietary low sodium salt called MicroSalt.”

Salarius have worked an agreement with a diversified snack manufacturer to include Microsalt in the production of company snacks. However, no financial terms of the contract have been published.

The patented Microsalt has been a product development funded by Tekcapital, and the success has paid off after landing this huge contract.

Tekcaptial have seemed to tap into an exciting market with the development of Microsalt.

The low sodium ingredients market is estimated to reach $1.76 billion by the end of 2025, with a compound annual growth rate of 11.7%.

By using Microsalt, firms are given the flexibility of creating the same snacks with less sodium content, without giving up quality and taste.

Shares in Tekcapital trade at 5p (+9.28%). 10/2/20 15:29BST.